Solid Q2
Sharekhan
Revenues stood at Rs. 627 crore, down 10% y-o-y and 5% q-o-q, 12% below our estimates.
Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
---|---|---|---|---|---|---|---|---|---|---|---|
12 Nov 2024 | Insecticides |
Sharekhan
|
765.30 | 949.00 | 778.85 (-1.74%) | 24.00 |
Buy
|
||||
12 Nov 2024 | Gateway Distriparks |
Sharekhan
|
61.79 | 105.00 | 86.23 (-28.34%) | 69.93 |
Buy
|
||||
12 Nov 2024 | Britannia Industries |
Sharekhan
|
5486.50 | 5995.00 | 5027.55 (9.13%) | 9.27 |
Buy
|
Margins miss mark; volume growth sustains
Sharekhan
Britannia’s Q2FY2025 numbers missed expectations due to lower-than-expected OPM at 16.8% (versus expectation of 19%) dragged down PAT by 9% y-o-y. Volume growth sustained at 8% better than large peers.
|
|||
12 Nov 2024 | Biocon |
Sharekhan
|
330.75 | 400.00 | 347.50 (-4.82%) | Target met |
Buy
|
||||
12 Nov 2024 | Bank of India |
Sharekhan
|
117.06 | 130.00 | 108.69 (7.70%) | 11.05 |
Buy
|
Mixed Q2, guiding for stability ahead
Sharekhan
Core operational performance was weak, led by muted NII driven by higher-than-expected NIM compression and higher opex growth (led by employee retiral provisions) despite healthy loan growth (~16% y-o-y). Core PPoP (ex. treasury gains) declined by 7% y-o-y.
|
|||
11 Nov 2024 | Asian Paints |
Sharekhan
|
2315.50 | 2779.00 | 2543.10 (-8.95%) | 20.02 |
Hold
|
Weak Q2; risk reward unfavourable
Sharekhan
Asian Paints Limited’s (APL’s) Q2FY2025 performance was a miss on all fronts with consolidated revenue declining by 5% y-o-y, OPM lower by 480 bps y-o-y to 15.4%; adjusted PAT decreased 34% y-o-y. Decorative paints’ volumes decreased by 0.5%.
|
|||
11 Nov 2024 | Zydus Wellness |
Sharekhan
|
1952.90 | 2465.00 | 1929.60 (1.21%) | 26.22 |
Buy
|
Mixed bag Q2
Sharekhan
Zydus Wellness Limited’s (ZWL’s) Q2FY2025 numbers were mixed with revenue growing by 12% y-o-y to Rs. 493 crore (versus Rs. 475 crore expected), while OPM stood flat y-o-y at 4% (against expectation of 5.3%). Adjusted PAT came in at Rs. 16 crore.
|
|||
11 Nov 2024 | Exide Industries |
Sharekhan
|
382.15 | 534.00 | 436.60 (-12.47%) | 39.74 |
Buy
|
||||
11 Nov 2024 | Divi's Laboratories |
Sharekhan
|
6483.00 | 6812.00 | 5899.95 (9.88%) | 5.07 |
Buy
|
||||
11 Nov 2024 | Aurobindo Pharma |
Sharekhan
|
1197.10 | 1532.00 | 1289.05 (-7.13%) | 27.98 |
Buy
|
Slight Dip in Profitability Due to Temporary Activities; Core Performance Strong
Sharekhan
Quarterly revenue reached Rs. 7,796 crore, up 8% y-o-y and 3% q-o-q, exceeding our estimates by 1%, while PAT was Rs. 817 crore, showing a 9% y-o-y increase but an 11% q-o-q decrease, falling 19% below our estimates.
|
|||
more
loading
|